Vlachostergios PJ - Search Results

1

An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer.

Nauseef JT, Villamar DM, Lebenthal J, Vlachostergios PJ, Tagawa ST. Nauseef JT, et al. Among authors: vlachostergios pj. Expert Opin Pharmacother. 2020 Jun;21(8):863-870. doi: 10.1080/14656566.2020.1736036. Epub 2020 Mar 3. Expert Opin Pharmacother. 2020. PMID: 32124650 Review.

2

Antibody therapeutics for treating prostate cancer: where are we now and what comes next?

Vlachostergios PJ, Galletti G, Palmer J, Lam L, Karir BS, Tagawa ST. Vlachostergios PJ, et al. Expert Opin Biol Ther. 2017 Feb;17(2):135-149. doi: 10.1080/14712598.2017.1258398. Epub 2016 Nov 20. Expert Opin Biol Ther. 2017. PMID: 27817214 Review.

3

Trimodality therapy in variant urothelial carcinoma: choose wisely.

Vlachostergios PJ, Jakubowski C, Tagawa ST. Vlachostergios PJ, et al. Transl Androl Urol. 2017 Apr;6(2):322-325. doi: 10.21037/tau.2017.03.59. Transl Androl Urol. 2017. PMID: 28540247 Free PMC article. No abstract available.

4

A critical review on ramucirumab in the treatment of advanced urothelial cancer.

Vlachostergios PJ, Lee A, Thomas C, Walsh R, Tagawa ST. Vlachostergios PJ, et al. Future Oncol. 2018 May;14(11):1049-1061. doi: 10.2217/fon-2017-0473. Epub 2017 Dec 12. Future Oncol. 2018. PMID: 29231057 Review.

5

Antibody-Drug Conjugates in Bladder Cancer.

Vlachostergios PJ, Jakubowski CD, Niaz MJ, Lee A, Thomas C, Hackett AL, Patel P, Rashid N, Tagawa ST. Vlachostergios PJ, et al. Bladder Cancer. 2018 Jul 30;4(3):247-259. doi: 10.3233/BLC-180169. Bladder Cancer. 2018. PMID: 30112436 Free PMC article. Review.

6

The molecular limitations of biomarker research in bladder cancer.

Vlachostergios PJ, Faltas BM. Vlachostergios PJ, et al. World J Urol. 2019 May;37(5):837-848. doi: 10.1007/s00345-018-2462-9. Epub 2018 Aug 31. World J Urol. 2019. PMID: 30171455 Review.

7

Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma.

Shohdy KS, Vlachostergios PJ, Abdel-Malek RR, Faltas BM. Shohdy KS, et al. Among authors: vlachostergios pj. Expert Opin Ther Targets. 2019 Feb;23(2):83-86. doi: 10.1080/14728222.2019.1559828. Epub 2018 Dec 17. Expert Opin Ther Targets. 2019. PMID: 30558440 No abstract available.

8

Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JM, Scherr DS, Sboner A, Tagawa ST, Molina AM, Elemento O, Nanus DM, Faltas BM. Karass M, et al. Among authors: vlachostergios pj. J Natl Compr Canc Netw. 2019 Mar 1;17(3):194-200. doi: 10.6004/jnccn.2018.7264. J Natl Compr Canc Netw. 2019. PMID: 30865916

9

Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis.

Vlachostergios PJ, Geyer JT, Miller J, Kosloff R, Beltran H, Tagawa ST. Vlachostergios PJ, et al. J Oncol Pract. 2019 Jun;15(6):343-345. doi: 10.1200/JOP.19.00012. Epub 2019 Apr 9. J Oncol Pract. 2019. PMID: 30964731 No abstract available.

10

Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.

Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J, Tagawa ST, Nanus DM, Beltran H, Molina AM, Khani F, Miguel Mosquera J, Xylinas E, Shariat SF, Scherr DS, Rubin MA, Lerner SP, Matin SF, Elemento O, Faltas BM. Robinson BD, et al. Among authors: vlachostergios pj. Nat Commun. 2019 Jul 5;10(1):2977. doi: 10.1038/s41467-019-10873-y. Nat Commun. 2019. PMID: 31278255 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

103 results

Search Page

Filters